Literature DB >> 15968253

Serum paraoxonase (a high-density lipoprotein-associated lipophilic antioxidant) activity and lipid profile in experimental acute pancreatitis.

Ethem Unal1, Hafize Uzun, Ramazan Kusaslan, Mustafa Dogan, Habibe Genc, Pembegul Gunes, Izzet Titiz.   

Abstract

OBJECTIVE: This study was designed to determine the serum lipid profile and the activity of paraoxonase (PON1, the lipophilic antioxidant component of high-density lipoprotein [HDL]-cholesterol) in acute pancreatitis.
METHODS: Acute pancreatitis was induced by injection of ethyl alcohol into the common biliary duct. Oxidative stress marker (malonyldialdehyde), lipid profile, and PON1 activity were determined in the serum.
RESULTS: In the acute pancreatitis group, whereas the mean levels of total cholesterol, low-density lipoproteins, and malonyldialdehyde were significantly higher (P < 0.001 for each), HDL level and PON1 activity were found to be significantly lower (P < 0.001 for each).
CONCLUSIONS: Our results suggest that an abnormal lipid profile and decreased PON1 activity may have a role in the pathogenesis of acute pancreatitis in which HDL-associated antioxidant defense is impaired.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15968253     DOI: 10.1097/01.mpa.0000168227.74203.e4

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  9 in total

1.  Biliopancreatic duct injection of ethanol as an experimental model of acute and chronic pancreatitis in rats.

Authors:  Ethem Unal; Suleyman Atalay; Huseyin Kerem Tolan; Sema Yuksekdag; Metin Yucel; Aylin Acar; Fatih Basak; Pembegul Gunes; Gurhan Bas
Journal:  Int J Clin Exp Med       Date:  2015-01-15

2.  Is elevated serum ceruloplasmin level associated with increased risk of coronary artery disease?

Authors:  Ayşe Yeşim Göçmen; Emel Sahin; Ender Semiz; Saadet Gümuşlü
Journal:  Can J Cardiol       Date:  2008-03       Impact factor: 5.223

3.  Serum paraoxonase undergoes inhibition and proteolysis during experimental acute pancreatitis.

Authors:  Neus Franco-Pons; Judit Marsillach; Jorge Joven; Jordi Camps; Daniel Closa
Journal:  J Gastrointest Surg       Date:  2008-03-11       Impact factor: 3.452

4.  Serum levels of apolipoprotein A-I and high-density lipoprotein can predict organ failure in acute pancreatitis.

Authors:  Yun-Shing Peng; Yung-Chang Chen; Ya-Chung Tian; Chih-Wei Yang; Jau-Min Lien; Ji-Tseng Fang; Cheng-Shyong Wu; Chien-Fu Hung; Tsan-Long Hwang; Ying-Huang Tsai; Mel S Lee; Ming-Hung Tsai
Journal:  Crit Care       Date:  2015-03-17       Impact factor: 9.097

5.  Decreased high density lipoprotein cholesterol is an independent predictor for persistent organ failure, pancreatic necrosis and mortality in acute pancreatitis.

Authors:  Yushun Zhang; Feng Guo; Shoukang Li; Feiyang Wang; Zibo Meng; Jingyuan Zhao; Zhiqiang Liu; Bo Wang; Ping Fan; Chunyou Wang; Heshui Wu
Journal:  Sci Rep       Date:  2017-08-14       Impact factor: 4.379

6.  Paraoxonase and arylesterase activities, lipid profile, and oxidative damage in experimental ischemic colitis model.

Authors:  Ethem Unal; Cengiz Eris; Bülent Kaya; Hafize Uzun; Faruk Cavdar; Murat Yildar; Ali Riza Kiziler; Birsen Aydemir; Pembegul Gunes; Riza Kutanis; Izzet Titiz
Journal:  Gastroenterol Res Pract       Date:  2012-11-12       Impact factor: 2.260

Review 7.  Serum paraoxonase 1 (PON1) measurement: an update.

Authors:  Jose J Ceron; Fernando Tecles; Asta Tvarijonaviciute
Journal:  BMC Vet Res       Date:  2014-03-25       Impact factor: 2.741

8.  High-Density Lipoprotein Cholesterol, Blood Urea Nitrogen, and Serum Creatinine Can Predict Severe Acute Pancreatitis.

Authors:  Wandong Hong; Suhan Lin; Maddalena Zippi; Wujun Geng; Simon Stock; Vincent Zimmer; Chunfang Xu; Mengtao Zhou
Journal:  Biomed Res Int       Date:  2017-08-22       Impact factor: 3.411

Review 9.  The Role of PON1 Variants in Disease Susceptibility in a Turkish Population.

Authors:  Mahmoud Abudayyak; Tuğçe Boran; Rumeysa Tukel; Ezgi Oztas; Gül Özhan
Journal:  Glob Med Genet       Date:  2020-08-31
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.